Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2/3, Multicenter, Single-Arm, Open-Label Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)

Next Previous
Trial Profile

A Phase 2/3, Multicenter, Single-Arm, Open-Label Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 24 May 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Encaleret (Primary)
  • Indications Hypocalcaemia
  • Focus Pharmacokinetics; Registrational
  • Acronyms CALIBRATE-PEDS
  • Sponsors Calcilytix therapeutics

Most Recent Events

  • 07 May 2026 According to the BridgeBio Pharma media release, company has dosed the first participant in the trial.
  • 14 Jan 2026 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Aug 2025 to 10 Feb 2026.
  • 14 Jan 2026 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top